Genomines | $45,000,000 | (Sep 18, 2025)
Synthesize Bio | $10,000,000 | (Sep 18, 2025)
Moby | $5,000,000 | (Sep 18, 2025)
Certified by Founder
Lodge
eGenesis, Inc.
start up
United States
- Cambridge, MA
- 04/09/2024
- Series B
- $191,000,000
eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis’ mission is to solve the global organ shortage crisis by developing a scalable alternative to allotransplantation.
eGenesis is reinvigorating the field of xenotransplantation by addressing the key virology and immunology hurdles that have prevented its advancement to date, and is developing commercially-viable products to save and improve the lives of patients who are waiting for an organ transplant.
- Industry Biotechnology Research
- Website https://egenesisbio.com/
- LinkedIn https://www.linkedin.com/company/egenesisbio/
Invisible Technologies | $100,000,000 | (Sep 18, 2025)
Mueon Corporation | $15,500,000 | (Sep 18, 2025)
Stablecore | $20,000,000 | (Sep 18, 2025)
Envive AI | $15,000,000 | (Sep 18, 2025)
Markup AI | $27,500,000 | (Sep 18, 2025)
Turnout | $21,000,000 | (Sep 18, 2025)
GridStrong | $10,000,000 | (Sep 18, 2025)
Imagine Pediatrics | $67,000,000 | (Sep 18, 2025)
Rec Technologies | $11,000,000 | (Sep 18, 2025)